13.99
1.23%
+0.17
After Hours:
13.99
TG Therapeutics Inc stock is currently priced at $13.99, with a 24-hour trading volume of 3.45M.
It has seen a +1.23% increased in the last 24 hours and a -7.04% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $13.84 pivot point. If it approaches the $14.12 resistance level, significant changes may occur.
TG Therapeutics Inc Stock (TGTX) Financials Data
TG Therapeutics Inc (TGTX) Revenue 2024
TGTX reported a revenue (TTM) of $233.66 million for the quarter ending December 31, 2023, a +8,293% rise year-over-year.
TG Therapeutics Inc (TGTX) Net Income 2024
TGTX net income (TTM) was $12.67 million for the quarter ending December 31, 2023, a +106.39% increase year-over-year.
TG Therapeutics Inc (TGTX) Cash Flow 2024
TGTX recorded a free cash flow (TTM) of -$31.41 million for the quarter ending December 31, 2023, a +82.17% increase year-over-year.
TG Therapeutics Inc (TGTX) Earnings per Share 2024
TGTX earnings per share (TTM) was $0.01 for the quarter ending December 31, 2023, a +100.68% growth year-over-year.
TG Therapeutics Inc Stock (TGTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Lonial Sagar | Director |
Mar 13 '24 |
Sale |
15.94 |
5,000 |
79,675 |
108,878 |
Charney Laurence N | Director |
Mar 12 '24 |
Sale |
15.97 |
22,000 |
351,340 |
215,229 |
Charney Laurence N | Director |
Jan 05 '24 |
Sale |
19.03 |
17,500 |
333,025 |
237,229 |
Power Sean A | CFO |
Jan 03 '24 |
Sale |
16.91 |
47,867 |
809,431 |
606,969 |
WEISS MICHAEL S | CEO and President |
Aug 11 '23 |
Buy |
10.13 |
100,000 |
1,013,000 |
12,073,021 |
Lonial Sagar | Director |
Jun 23 '23 |
Sale |
23.37 |
34,854 |
814,538 |
93,878 |
Power Sean A | Chief Financial Officer |
Jun 02 '23 |
Sale |
26.70 |
73,647 |
1,966,375 |
654,836 |
TG Therapeutics Inc Stock (TGTX) Latest News
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
GlobeNewswire Inc.
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
GlobeNewswire Inc.
Rare Stock Picks In February 2024 - From 32 Discerning Analysts
Seeking Alpha
About TG Therapeutics Inc
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Cap:
|
Volume (24h):